HealthLeaders Media (4/3, Commins) reports, “Nearly 57 million adult Americans have a substance abuse or mental health condition, and nearly 40 million of them go untreated, according to data cited by the Government Accountability Office.” The data was from a 2017 survey administered by the Substance Abuse and Mental Health Services Administration (SAMHSA), which “found that people who perceived a need for behavioral health treatment but did not receive it blamed cost, stigma, and access challenges, such as not knowing where to go for treatment.” The report said, “According to experts GAO met with, available research in this area is limited by methodological challenges, including determining which healthcare costs can be attributed to an untreated behavioral condition, and by limited data on the full prevalence of certain behavioral health conditions.”

Related Links:

— “GAO: Most People With Substance Abuse, Mental Health Disorders Go Untreated, “John Commins, HealthLeaders Media, April 3, 2019

HealthDay (3/28, Preidt) reported researchers found that the combination of premature birth and having a fussy baby can increase the mother’s risk of depression. The findings were published online in Academic Pediatrics.

Related Links:

— “Fussy Baby May Raise Mom’s Risk of Depression, “Robert Preidt, HealthDay, March 28, 2019

Healio (4/1, Demko) reports, “Veterans with” post-traumatic stress disorder (PTSD) “and major depressive disorder [MDD] saw significant improvement in suicidal ideation after receiving IV infusions of ketamine over a 12-day period,” researchers concluded. The findings of the 15-veteran study were presented as a poster at the Anxiety and Depression Association of America’s annual conference.

Related Links:

— “Ketamine improves suicidal ideation in veterans with PTSD, MDD, “Savannah Demko, Healio, April 01, 2019

In “Health & Science,” the Washington Post (3/29, Marcus) delved into the debate among physicians whether “genetic testing helps” them “better prescribe antidepressants.” Last November, “the Food and Drug Administration…released a statement warning patients and doctors to be cautious about genetic testing that has not been approved by the FDA, including those that guide the prescribing of antidepressants.” The statement, prepared by the directors of the Center for Devices and Radiological Health and of the Center for Drug Evaluation and Research, said, “The FDA is aware of genetic tests that claim results can be used by physicians to identify which antidepressant medication would have increased effectiveness or side effects compared to other antidepressant medications.” Nevertheless, “the relationship between DNA variations and the effectiveness of antidepressant medications has never been established,” the statement added.

Related Links:

— “Can genetic testing help doctors better prescribe antidepressants? There’s quite a debate, “Ilana Marcus, The Washington Post, March 29, 2019

Forbes (3/31, Disalvo) contributor David DiSalvo wrote, “Findings from a new study” published online March 22 in Nature Digital Medicine “suggest that users should be cautious” when it comes to mental health apps that claim “to effectively diagnose and manage several disorders.” The study found that “not only do few of the apps rely on real-world experience in their design,” but also that “most also lack any credible scientific evidence to support their claims.” Investigators arrived at these findings after having “identified 1,435 mental health apps from the two most popular app stores (iTunes and Google Play), and then” focusing “on 73 of the apps ‘representing the most highly ranked’ to evaluate their claims.” The study authors also noted that “these findings are important as industry certification options are discussed to improve offerings to consumers, along with screening of apps by accredited organizations like the American Psychiatric Association.”

Related Links:

— “Study: Mental Health Apps Are Loaded With Scientific Language, But Light On Scientific Evidence, “David DiSalvo, Forbes, March 31, 2019